$OCGN JB Highlights: - the vaccine effort will become more granular. Which means reaching people where they are and an easy to store solution will be important to this. - a push to roll out with young people. Pfizer will be first and won’t be suitable for all young people with pre existing medical conditions. Our safety profile is top notch. - reaching the hard to reach. Here’s the point it becomes more complex and expensive. Vaccine prices will go up as we slowly shift to endemic status. Combating variants will be a crucial part of the roll out to flatten infection rates and avoid a third/fourth wave.